Picture of Kaneka logo

4118 — Kaneka News Story

0.000.00%
jp flag iconLast trade - 00:00
Basic MaterialsConservativeMid CapSuper Stock

Inovio: Rises on manufacturing deal for COVID-19 vaccine candidate

** Shares of drug developer Inovio Pharmaceuticals Inc
 INO.O  up 3.59% at $12.4 premarket
    ** INO announces deal with Kaneka Eurogentec S.A., an
affiliate of Japan's Kaneka Corp  4118.T , to make INO's
COVID-19 vaccine candidate INO-4800; deal terms were not
disclosed  urn:newsml:reuters.com:*:nPn9ZPgd2a
    ** INO has already partnered with Thermo Fisher Scientific,
Richter-Helm BioLogics and Ology Biosciences to manufacture the
potential vaccine
    ** Co is currently running the Phase 2 segment of its
planned Phase 2/3 clinical trial for INO-4800 against COVID-19
 urn:newsml:reuters.com:*:nL4N2I22ZI
    ** The U.S. FDA in September had put the Phase 3 portion of
the mid-to-late stage trial on hold, as it sought more
information, including details on a delivery device
    ** Up to Wednesday's close, INO up ~263% YTD

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))

Recent news on Kaneka

See all news